Back

Incidence and clinical characteristics of cardiac amyloidosis in Tuscany and Umbria

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: The different faces of cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Vincenzo Castiglione

Fondazione Toscana Gabriele Monasterio, Pisa (Italy)

9 More presentations in this session

Presentation thumbnail
Sustained paradoxical vasodilation and blood pressure lowering in response to sympathetic stimulation as markers of disease severity and poor survival in primary AL amyloidosis.
Doctor K. Stamatelopoulos (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Changes in the diagnostic landscape of transthyretin amyloid cardiomyopathy (ATTR-CM): a comparison of tests ordered and test Intervals in 2020 Q4 and 2023 Q4
Mr P. Collins (London, GB)
Abstract Slides Video
Presentation thumbnail
Frailty and associated outcomes in patients with transthyretin cardiac amyloidosis
Doctor C. Fumagalli (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Cardiac transthyretin amyloidosis in patients with conduction system disease
Doctor J. Pudich (Ostrava, CZ)
Abstract Slides Video
Presentation thumbnail
ATTR cardiac amyloidosis after lumbar spinal stenosis- a prospective cohort study
Doctor P. Eldhagen (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
The different faces of cardiac amyloidosis

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Impact of the non-invasive diagnostic algorithm on clinical presentation and prognosis in a nationwide multicentric light-chain and transthyretin-related cardiac amyloidosis cohort
thumbnail
Congress Presentation
High prevalence of cardiac amyloidosis with increasing age
thumbnail
Congress Presentation
Investigation of the prevalence of cardiac amyloidosis among patients with echocardiographically verified myocardial hypertrophy of unknown etiology

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources